ImmuPharma PLC Total Assets
ImmuPharma PLC total assets. Based on the latest financial reports, ImmuPharma PLC (IMM) holds total assets worth GBX1.58 Million GBX (≈ $192.34 USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ImmuPharma PLC (IMM) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of ImmuPharma PLC (2004–2024)
Total assets of ImmuPharma PLC from 2004 to 2024. This chart illustrates how ImmuPharma PLC's total assets have evolved over time, based on quarterly financial data. See ImmuPharma PLC stock price for real-time trading data and today's change.
ImmuPharma PLC - Asset Composition Analysis
ImmuPharma PLC Total Assets Breakdown (December 2024)
ImmuPharma PLC total assets breakdown as of December 2024. ImmuPharma PLC's total assets of GBX1.58 Million consist of 90.6% current assets and 9.4% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 24.3% |
| Accounts Receivable | GBX429.15K | 43.9% |
| Inventory | GBX0.00 | 0.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX9.82K | 1.0% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2004–2024)
This chart illustrates how ImmuPharma PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ImmuPharma PLC working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ImmuPharma PLC's current assets represent 90.6% of total assets in 2024, a decrease from 100.0% in 2004.
- Cash Position: Cash and equivalents constituted 24.3% of total assets in 2024, down from 99.8% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 43.9% of total assets.
ImmuPharma PLC Competitors by Total Assets
Key competitors of ImmuPharma PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
ImmuPharma PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.21 | 1.60 | 5.89 |
| Quick Ratio | 1.21 | 1.60 | 5.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX257.41K | GBX819.08K | GBX6.17 Million |
ImmuPharma PLC - Advanced Valuation Insights
This section examines the relationship between ImmuPharma PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 107.20 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | -64.1% |
| Total Assets | GBX977.01K |
| Market Capitalization | $201.24K USD |
Valuation Analysis
Below Book Valuation: The market values ImmuPharma PLC's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ImmuPharma PLC's assets decreased by 64.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ImmuPharma PLC (2004–2024)
The table below shows the annual total assets of ImmuPharma PLC from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX977.01K ≈ $118.87 |
-64.10% |
| 2023-12-31 | GBX2.72 Million ≈ $331.12 |
-31.53% |
| 2022-12-31 | GBX3.97 Million ≈ $483.61 |
-33.73% |
| 2021-12-31 | GBX6.00 Million ≈ $729.76 |
-45.05% |
| 2020-12-31 | GBX10.92 Million ≈ $1.33K |
+88.17% |
| 2019-12-31 | GBX5.80 Million ≈ $705.82 |
-33.00% |
| 2018-12-31 | GBX8.66 Million ≈ $1.05K |
+72.56% |
| 2017-12-31 | GBX5.02 Million ≈ $610.46 |
-25.23% |
| 2016-12-31 | GBX6.71 Million ≈ $816.39 |
+108.83% |
| 2015-12-31 | GBX3.21 Million ≈ $390.94 |
-54.57% |
| 2014-12-31 | GBX7.07 Million ≈ $860.50 |
-1.84% |
| 2013-12-31 | GBX7.21 Million ≈ $876.67 |
-31.44% |
| 2012-12-31 | GBX10.51 Million ≈ $1.28K |
-26.40% |
| 2011-12-31 | GBX14.28 Million ≈ $1.74K |
-18.65% |
| 2010-12-31 | GBX17.55 Million ≈ $2.14K |
-28.77% |
| 2009-12-31 | GBX24.64 Million ≈ $3.00K |
+83.88% |
| 2008-12-31 | GBX13.40 Million ≈ $1.63K |
+226.88% |
| 2007-12-31 | GBX4.10 Million ≈ $498.85 |
-44.03% |
| 2006-12-31 | GBX7.33 Million ≈ $891.24 |
+101.96% |
| 2006-03-31 | GBX3.63 Million ≈ $441.30 |
+260.18% |
| 2005-03-31 | GBX1.01 Million ≈ $122.52 |
+2.76% |
| 2004-03-31 | GBX980.00K ≈ $119.24 |
-- |
About ImmuPharma PLC
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company's lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lup… Read more